Nanotechnology Now

Our NanoNews Digest Sponsors





Heifer International

Wikipedia Affiliate Button


android tablet pc

Home > Press > Orphan in need of adoption

Abstract:
Nano therapy for ovarian cancer will enable superior tumor accumulation and retention of radioactivity, resulting in better therapuetic efficacy than existing standards of care.

Orphan in need of adoption

Philadelphia, PA | Posted on December 8th, 2006

Twenty thousand new cases of ovarian cancer are diagnosed in the United States each year. More than 75% of these patients are women with late stage ovarian cancer. The prognosis for this group is very poor: only 30% will survive five years or longer.

Even treatment for ovarian cancer can be devastating to a patient's quality of life. Treatment commonly involves invasive surgery followed by extensive chemotherapy, both of which can be physically and emotionally traumatic.

Under funding received from The Nanotechnology Institute and the National Cancer Institute, University of Pennsylvania Scientists have created a nanotechnology-based radiopharmaceutical that could potentially improve the treatment of ovarian cancer.

The proprietary platform technology specifically targets cancer cells via the folate receptor pathway, minimizing damage to surrounding non-cancerous cells. In principle, the drug will enable a higher tumor radiation dose than is possible with other radiotherapeutics, which do not deliver enough radiation to be useful for treatment.

Unfortunately, despite tremendous laboratory progress, this technology may never reach the patients who need it most. The reason is that the market opportunity for ovarian cancer is small (~$75M/year) - too small to justify development by a large multinational corporation.

"This is a platform technology with enormous potential, but its early stage means there is also enormous clinical risk," says Dr. Brian Smith, a co-inventor of the technology. "Our work with Greg Adams at the Fox Chase Cancer Center is promising, but it suggests the need for additional experiments."

Usually at this stage of development, a sponsoring company would invest and work with the scientist to further the research. However, the small market size is a significant barrier to attracting would-be investors. Dr. Smith also hopes to keep the drug affordable, launching at a price of around $5,000 instead of the $50,000 that could be charged for this type of therapy.

"What we need is an angel with personal interest," says Hugo Fitzgerald, Manager of Nanotechnology and Licensing at the University of Pennsylvania. "We have an adequate IP portfolio to justify the creation of a small start up, what we lack is the outside management to champion it and push it out of the laboratory and into the FDA approval process."

The therapeutic would likely qualify for tax credits and marketing exclusivity under the Orphan Drug Act, priority FDA review, and accelerated FDA approval. Follow on applications could include treatments for various other cancers as well as a related radiopharmaceutical for diagnostic imaging.

If interested in working with or supporting the research, please contact:

Hugo FitzGerald
Manager Nanotechnology and Licensing
Center for Technology Transfer
University of Pennsylvania

####

For more information, please click here

Contacts:
Contact: Hugo FitzGerald
Phone: 215 573 4307
Fax:
E-mail:

Copyright © University of Pennsylvania

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

Investments/IPO's/Splits

Harris & Harris Group Notes the Receipt of Proceeds From the Sale of Molecular Imprints' Semiconductor Business to Canon April 22nd, 2014

Harris & Harris Group Continues Its Blog Series to Highlight Most Impactful Portfolio Companies With Champions Oncology, Inc. April 17th, 2014

Nanometrics to Announce First Quarter Financial Results on April 29, 2014 April 9th, 2014

Harris & Harris Group Notes Mersana's Collaboration Agreement With Subsidiary of Takeda Pharmaceutical Co. April 8th, 2014

Nanomedicine

University of Tehran Researchers Invent Non-Enzyme Sensor to Detect Blood Sugar April 23rd, 2014

Gold nanoparticles help target, quantify breast cancer gene segments in a living cell April 23rd, 2014

QuantuMDx announce prototype handheld lab for 15 minute malaria diagnosis and drug resistance testing April 23rd, 2014

Study finds long-term survival of human neural stem cells transplanted into primate brain April 23rd, 2014

Announcements

Characterizing inkjet inks: Malvern Instruments presents new rheological research April 23rd, 2014

NanoSafe, Inc. announces the addition of the Labconco Protector® Glove Box to its NanoSafe Tested™ registry April 23rd, 2014

Study finds long-term survival of human neural stem cells transplanted into primate brain April 23rd, 2014

High-Performance, Low-Cost Ultracapacitors Built with Graphene and Carbon Nanotubes: Future devices based on technology could bridge gap between batteries and conventional capacitors in portable electronics and hybrid electric vehicles April 23rd, 2014

Human Interest/Art

Harry Potter-style invisibility cloaks: A real possibility next Christmas? Forget socks and shaving foam, the big kids of tomorrow want an invisible cloak for Christmas December 19th, 2013

Chicago Awareness Organization First Not-for-Profit to Sponsor Dog Training to Detect Ovarian Cancer Odorants December 12th, 2013

ZEISS Microscopes used to create images for Art Exhibit at Midway Airport: Art of Science: Images from the Institute for Genomic Biology October 25th, 2013

New potential for touch screens found at your fingertips September 17th, 2013

NanoNews-Digest
The latest news from around the world, FREE







  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More














ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







© Copyright 1999-2014 7th Wave, Inc. All Rights Reserved PRIVACY POLICY :: CONTACT US :: STATS :: SITE MAP :: ADVERTISE